|Female luteal phase defect.|
|Dysfunctional uterine bleeding,|
|Threatened and habitualmiscarriage during early pregnancy.|
|10,000 IU on early diagnosis of pregnancy.|
|5,000 IU twice per week up to week 12.|
|5,000 IU once per week up to week 16.|
|2,500 - 5,000 IU three times/week until bleeding cease & pregnancy establish.|
|5,000 or 10,000 IU single dose on 13th day of cycle.|
Vascular permeability increases significantly so that body fluids in the chest, abdominal cavity and pericardial cavity accumulate rapidly resulting in a variety of complications, such as blood volume reduction, electrolyte imbalance, hemoconcentration, abdominal bleeding, thrombosis ormation. Clinical manifestations are intense pain of abdomen or pelvic, dyspepsia, edema, urine volume reduction, nausea, vomiting or diarrhea, shortness of breath and lower extremity swelling. Those symptoms occur 7 ~ 10 days after ovulation or when the treatment is over. Severe symptoms are life-threatening.
Rare side effects: breast swelling, headache, excitability, mental depression, easy fatigue.
Occasional local injection pain, allergic skin rash.
Patients of suspected pituitary hyperplasia or tumor, prostate cancer or other patients with androgen-related tumor are contraindicated. Patients of precocious puberty, the undetermined diagnosis of vaginal bleeding, uterine fibroids, ovarian cysts or ovarian enlargement, thrombosis phlebitis and gonadotropin-allergic patients are all contraindicated.
Pregnancy and lactation:
|Use with caution.|
|For elderly patients, the potential possibility of inducing androgen related tumor should be considered. The dosage should decrease along with decreased physiological function.|
|When combined with pituitary gonadotropin (eg, HMG), adverse reactions may increase. It should be used with caution.|
|Overdose: Not clear.|
|Storage: Protect from light and keep tightly sealed in a cool place.|
|Package: 5000 IU/vial, 1 vial/box (1 vial + 1 ampoule of sodium chloride injection)|